Tenax Therapeutics(TENX) - 2024 Q3 - Quarterly Results

EX-99.1 2 tenx_ex991.htm PRESS RELEASE EXHIBIT 99.1 Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., November 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, devel ...